SEC Form 4 · accession 0001179022-18-000045
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack W Callicutt
Officer — Chief Financial Officer
Period of report
May 31, 2018
Accepted (ET)
Jun 4, 2018 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 31, 2018 | M | 46,651 | $0.87 | A | 47,911 | D | |
| Common Stock | May 31, 2018 | S | 46,651 | $5.00 | D | 1,260 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $0.87 | May 31, 2018 | M | 46,651 | D | — | Dec 3, 2026 | Common Stock | 46,651 | 100,000 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018.
- F2The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017.